NIBSC - Reagents

Enter a search term

Home Page > Spotlight > Influenza Resource Centre > Reagents

Reagents

Full Reagent Update

Current availability from NIBSC of candidate influenza vaccine viruses, SRD reagents and neuraminidase reagents for use in the 2012/2013 northern hemisphere and the 2012 southern hemisphere season. (See below for pricing information)

Update 32, 30th April 2012

Northern Hemisphere 2012/2013¹

Candidate influenza vaccine viruses	NIBSC code
H1N1
A/California/7/2009 wild type virus	10/122
NYMC X-179A reassortant derived from A/California/7/2009	11/112
NYMC X-181 reassortant derived from A/California/7/2009	11/128
NIBRG-121xp reassortant derived from A/California/7/2009	09/268
NIBRG-122 reassortant derived from A/England/195/2009 (A/California/7/2009 – like)	09/130
NIB-74xp reassortant derived from A/Christchurch/16/2010 (A/California/7/2009 – like)	11/186
H3N2
A/Victoria/361/2011 wild type virus	11/226
IVR-165 reassortant derived from A/Victoria/361/2011	11/220
NIB-79 reassortant derived from A/Victoria/361/2011	11/222
NYMC X-217 reassortant derived from A/Victoria/361/2011	12/100
B
B/Wisconsin/1/2010 wild type virus	11/224
B/Texas/6/2011 wild type virus (B/Wisconsin/1/2010 – like)	11/232
NYMC BX-39 reassortant derived from B/Hubei Wujiagang/158/2009 (B/Wisconsin/1/2010 – like)	10/270
NYMC BX-49 reassortant derived from B/Texas/6/2011 (B/Wisconsin/1/2010 – like)	11/244
NYMC BX-41A reassortant derived from B/Wisconsin/1/2010	11/240

Reagents for influenza vaccine standardisation	NIBSC code
H1N1
A/California/7/2009 (NYMC X-179A) egg derived antigen	09/146
A/California/7/2009 (NYMC X-179A) cell derived antigen	09/174
A/California/7/2009 (NIBRG-121xp) egg derived antigen	09/196
A/California/7/2009 (NYMC X-181)	11/202
A/California/7/2009 (NYMC X-181) Replacement reagent required	TBC
A/Christchurch/16/2010 (NIB-74)	10/258
A/Brisbane/10/2010 cell derived antigen	11/134
A/California/7/2009 antiserum	11/238
H3N2
A/Victoria/361/2011 (IVR-165) egg derived antigen Reagent scheduled to be filled 10 May	12/114
A/Victoria/361/2011 antiserum Reagent scheduled to be filled 04 May	12/116
B
B/Hubei Wujiagang/158/2009 (NYMC BX-39) egg derived antigen Available now	12/106
B/Wisconsin/1/2010 cell derived antigen Reagent scheduled to be available week beginning 07 May	12/110
B/Hubei Wujiagang/158/2009 antiserum Reagent scheduled to be filled 09 May	12/118

Neuraminidase reagents	NIBSC code
N1
Antiserum prepared from A/California/7/2009	10/218
antiserum prepared from A/New Caledonia/20/99	04/230
N2
antiserum prepared from A/Wyoming/3/2003	04/258
B
NA antiserum prepared from B/Jiangsu/10/2003	04/228
NA antiserum prepared from B/Malaysia/2506/2004	05/252
NA antiserum prepared for B/Florida/4/2006	09/316

Southern Hemisphere 2012²

Candidate influenza vaccine viruses	NIBSC code
H1N1
A/California/7/2009 wild type virus	10/122
NYMC X-179A reassortant derived from A/California/7/2009	11/112
NYMC X-181 reassortant derived from A/California/7/2009	11/128
NIBRG-121xp reassortant derived from A/California/7/2009	09/268
NIBRG-122 reassortant derived from A/England/195/2009	09/130
NIB-74xp reassortant derived from A/Christchurch/16/2010(A/California/7/2009 – like)	11/186
H3N2
A/Perth/16/2009 wild type virus	11/106
NIB-64 reassortant derived from A/Perth/16/2009	09/280
NYMC X-183 reassortant derived from A/Wisconsin/15/2009	09/248
NYMC X-185 reassortant derived from A/Guangdong-Luohu/1256/2009	09/274
NYMC X-187 reassortant derived from A/Victoria/210/2009	11/108
NIB-65 reassortant derived from A/Victoria/210/2009	09/298
IVR-155 reassortant derived from A/Victoria/210/2009	09/304
B
B/Brisbane/60/2008	10/244
B/Brisbane/33/2008	08/280
NYMC BX-31 reassortant derived from B/Brisbane/60/2008	10/276
NYMC BX-35 reassortant derived from B/Brisbane/60/2008	09/318
NYMC BX-39 reassortant derived from B/Hubei Wjiagang/158/2009	10/270

² http://www.who.int/influenza/vaccines/virus/recommendations/2012south/en/

Reagents for influenza vaccine standardisation	NIBSC code
H1N1
A/California/7/2009 (NYMC X-179A) egg derived antigen	09/146
A/California/7/2009 (NYMC X-179A) cell derived antigen	09/174
A/California/7/2009 (NIBRG-121xp) egg derived antigen	09/196
A/California/7/2009 (NIBRG-121xp) egg derived antigen	11/202
A/Christchurch/16/2010 (NIB-74)	10/258
A/Brisbane/10/2010 cell derived antigen	11/134
A/California/7/2009 antiserum	11/238
H3N2
A/Perth/16/2009 like antigen A/Wisconsin/15/2009 (NYMC X-183)	09/310
A/Perth/16/2009 like antigen A/Victoria/210/2009 (NYMC X-187) Replacement reagent scheduled to be filled 03 May	12/112
A/Perth/16/2009 like antiserum	11/206
B
B/Brisbane/60/2008 antigen	08/352
B/Brisbane/60/2008 like antigen (NYMC BX-35)	10/106
B/Brisbane/60/2008 like antiserum	11/136

Neuraminidase reagents	NIBSC code
N1
Antiserum prepared from A/California/7/2009	10/218
Antiserum prepared from A/New Caledonia/20/99	04/230
N2
Antiserum prepared from A/Wyoming/3/2003	04/258
B
NA antiserum prepared from B/Jiangsu/10/2003	04/228
NA antiserum prepared from B/Malaysia/2506/2004	05/252
NA antiserum prepared for B/Florida/4/2006	09/316

Pricing information

Viruses are free of charge (normally a maximum of two vials per recipient), but customers are expected to pay shipping and packing costs. Reagents for Single Radial Diffusion assay are subject to the usual NIBSC handling charge of £66 per vial, plus shipping and packing costs. Approved National Control Laboratories for human health are exempt from the £66 handling fee.